Compounds > 4-amino-5-(pyridin-4-yl)-4h-1,2,4-triazole-3-thiol
Page last updated: 2024-11-09

4-amino-5-(pyridin-4-yl)-4h-1,2,4-triazole-3-thiol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-amino-5-(pyridin-4-yl)-4H-1,2,4-triazole-3-thiol: a ligand of some antineoplastic metal complexes; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID719823
CHEMBL ID571510
SCHEMBL ID1164883
SCHEMBL ID13983997
MeSH IDM000613437

Synonyms (38)

Synonym
36209-51-5
inchi=1/c7h7n5s/c8-12-6(10-11-7(12)13)5-1-3-9-4-2-5/h1-4h,8h2,(h,11,13
4-amino-5-(4-pyridyl)-4h-1,2,4-triazole-3-thiol, 97%
4-amino-5-(pyridin-4-yl)-4h-1,2,4-triazole-3-thiol
STK267425
OPREA1_782938
AKOS000266760
4-amino-3-pyridin-4-yl-1h-1,2,4-triazole-5-thione
CHEMBL571510 ,
4-amino-5-(4-pyridinyl)-2,4-dihydro-3h-1,2,4-triazole-3-thione
AO-476/14512072
4-amino-3-(pyridin-4-yl)-1h-1,2,4-triazole-5(4h)-thione
4-amino-5-pyridin-4-yl-4h-[1,2,4]triazole-3-thiol
bdbm50320721
STK729254
4-amino-5-(pyridin-4-yl)-2,4-dihydro-3h-1,2,4-triazole-3-thione
A823165
AKOS005525604
F1219-1516
FT-0639307
LHSIJUVRXSETDR-UHFFFAOYSA-N
SCHEMBL1164883
9G-443S
SCHEMBL13983997
3h-1,2,4-triazole-3-thione, 4-amino-2,4-dihydro-5-(4-pyridinyl)-
4-amino-5-pyridin-4-yl-4h-1,2,4-triazole-3-thiol
4-amino-5-(4-pyridyl)-4h-1,2,4-triazole-3-thiol
4-amino-5-(4-pyridyl)-4 h-1,2,4-triazole-3-thiol
mfcd00274215
DTXSID80352135
4-amino-5-(pyridin-4-yl)-1,2,4-triazole-3-thione
4-amino-3-(4-pyridyl)-1,2,4-triazole-5(4h)-thione
3-pyridinyl-4-amino-5-mercapto-1,2,4-triazole
F17129
SY082974
CS-0157395
EN300-16511
Z55981935
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AcetylcholinesteraseElectrophorus electricus (electric eel)IC50 (µMol)13.46000.00000.94539.9400AID1126626
Polyphenol oxidase 2Agaricus bisporusKi1.01000.00063.28838.8900AID488234
CholinesteraseHomo sapiens (human)IC50 (µMol)49.58000.00001.559910.0000AID1126627
Intestinal-type alkaline phosphataseBos taurus (cattle)IC50 (µMol)4.43000.35002.88337.3400AID1126628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processCholinesteraseHomo sapiens (human)
learningCholinesteraseHomo sapiens (human)
negative regulation of cell population proliferationCholinesteraseHomo sapiens (human)
neuroblast differentiationCholinesteraseHomo sapiens (human)
peptide hormone processingCholinesteraseHomo sapiens (human)
response to alkaloidCholinesteraseHomo sapiens (human)
cocaine metabolic processCholinesteraseHomo sapiens (human)
negative regulation of synaptic transmissionCholinesteraseHomo sapiens (human)
response to glucocorticoidCholinesteraseHomo sapiens (human)
response to folic acidCholinesteraseHomo sapiens (human)
choline metabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic processCholinesteraseHomo sapiens (human)
dephosphorylationIntestinal-type alkaline phosphataseBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
amyloid-beta bindingCholinesteraseHomo sapiens (human)
catalytic activityCholinesteraseHomo sapiens (human)
acetylcholinesterase activityCholinesteraseHomo sapiens (human)
cholinesterase activityCholinesteraseHomo sapiens (human)
protein bindingCholinesteraseHomo sapiens (human)
hydrolase activity, acting on ester bondsCholinesteraseHomo sapiens (human)
enzyme bindingCholinesteraseHomo sapiens (human)
choline bindingCholinesteraseHomo sapiens (human)
identical protein bindingCholinesteraseHomo sapiens (human)
magnesium ion bindingIntestinal-type alkaline phosphataseBos taurus (cattle)
alkaline phosphatase activityIntestinal-type alkaline phosphataseBos taurus (cattle)
zinc ion bindingIntestinal-type alkaline phosphataseBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
extracellular regionCholinesteraseHomo sapiens (human)
nuclear envelope lumenCholinesteraseHomo sapiens (human)
endoplasmic reticulum lumenCholinesteraseHomo sapiens (human)
blood microparticleCholinesteraseHomo sapiens (human)
plasma membraneCholinesteraseHomo sapiens (human)
extracellular spaceCholinesteraseHomo sapiens (human)
side of membraneIntestinal-type alkaline phosphataseBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID448145Antimicrobial activity against Bacillus cereus 702 Roma after 18 hrs by well diffusion method2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis of some new 1,2,4-triazoles starting from isonicotinic acid hydrazide and evaluation of their antimicrobial activities.
AID1126634Anticancer activity against human NCI-H157 cells at 10 uM after 48 hrs by SRB assay2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis, crystal structure and biological evaluation of some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines.
AID448140Antimicrobial activity against Escherichia coli ATCC 25922 after 18 hrs by well diffusion method2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis of some new 1,2,4-triazoles starting from isonicotinic acid hydrazide and evaluation of their antimicrobial activities.
AID1126631Anticancer activity against Syrian golden hamster BHK21 cells at 1 uM after 48 hrs by SRB assay2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis, crystal structure and biological evaluation of some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines.
AID488234Inhibition of mashroom tyrosinase2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triazole-5(4H)-thiones, and substituted hydrazides to the dicopper active site.
AID1126636Anticancer activity against human NCI-H157 cells at 0.1 uM after 48 hrs by SRB assay2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis, crystal structure and biological evaluation of some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines.
AID1126632Anticancer activity against Syrian golden hamster BHK21 cells at 0.1 uM after 48 hrs by SRB assay2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis, crystal structure and biological evaluation of some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines.
AID448144Antimicrobial activity against Staphylococcus aureus ATCC 25923 after 18 hrs by well diffusion method2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis of some new 1,2,4-triazoles starting from isonicotinic acid hydrazide and evaluation of their antimicrobial activities.
AID1126638Antileishmanial activity against promastigote form of Leishmania major at 10 uM after 72 hrs by MTT assay2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis, crystal structure and biological evaluation of some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines.
AID1126633Anticancer activity against human NCI-H157 cells at 100 uM after 48 hrs by SRB assay2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis, crystal structure and biological evaluation of some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines.
AID1126635Anticancer activity against human NCI-H157 cells at 1 uM after 48 hrs by SRB assay2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis, crystal structure and biological evaluation of some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines.
AID1126639Antileishmanial activity against promastigote form of Leishmania major at 1 uM after 72 hrs by MTT assay2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis, crystal structure and biological evaluation of some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines.
AID1126626Inhibition of electric eel acetylcholinesterase using acetylthiocholine iodide as substrate preincubated for 10 mins before substrate addition after 15 mins by Ellman's method2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis, crystal structure and biological evaluation of some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines.
AID448141Antimicrobial activity against Yersinia pseudotuberculosis ATCC 911after 18 hrs by well diffusion method2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis of some new 1,2,4-triazoles starting from isonicotinic acid hydrazide and evaluation of their antimicrobial activities.
AID1126637Antileishmanial activity against promastigote form of Leishmania major at 100 uM after 72 hrs by MTT assay2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis, crystal structure and biological evaluation of some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines.
AID1126630Anticancer activity against Syrian golden hamster BHK21 cells at 10 uM after 48 hrs by SRB assay2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis, crystal structure and biological evaluation of some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines.
AID1126628Inhibition of calf intestinal alkaline phosphatase using p-nitrophenyl phosphate as substrate preincubated for 10 mins before substrate addition after 30 mins2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis, crystal structure and biological evaluation of some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines.
AID448143Antimicrobial activity against Enterococcus faecalis ATCC 29212 after 18 hrs by well diffusion method2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis of some new 1,2,4-triazoles starting from isonicotinic acid hydrazide and evaluation of their antimicrobial activities.
AID448147Antimicrobial activity against Candida albicans ATCC 60193 after 18 hrs by well diffusion method2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis of some new 1,2,4-triazoles starting from isonicotinic acid hydrazide and evaluation of their antimicrobial activities.
AID448142Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 after 18 hrs by well diffusion method2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis of some new 1,2,4-triazoles starting from isonicotinic acid hydrazide and evaluation of their antimicrobial activities.
AID1126627Inhibition of human BChE using butyrylthiocholine iodide as substrate preincubated for 10 mins before substrate addition after 15 mins by Ellman's method2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis, crystal structure and biological evaluation of some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines.
AID448146Antimicrobial activity against Candida tropicalis ATCC 13803 after 18 hrs by well diffusion method2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Synthesis of some new 1,2,4-triazoles starting from isonicotinic acid hydrazide and evaluation of their antimicrobial activities.
AID1126640Antileishmanial activity against promastigote form of Leishmania major at 0.1 uM after 72 hrs by MTT assay2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis, crystal structure and biological evaluation of some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines.
AID1126629Anticancer activity against Syrian golden hamster BHK21 cells at 100 uM after 48 hrs by SRB assay2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis, crystal structure and biological evaluation of some novel 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.84 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
4-hydroxybenzoic acid hydrazide
4-hydroxybenzoic acid hydrazide: metabolite of nifuroxazide. 4-hydroxybenzohydrazide : A carbohydrazide obtained by formal condensation of the carboxy group of 4-hydroxybenzoic acid with hydrazine.		2.0510carbohydrazide;
phenols
donepezil
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.. donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.. 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.		2.110aromatic ether;
indanones;
piperidines;
racemate		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent
fluconazole
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.		2.0510conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
kojic acid
[no description available]		2.05104-pyranones;
enol;
primary alcohol		Aspergillus metabolite;
EC 1.10.3.1 (catechol oxidase) inhibitor;
EC 1.10.3.2 (laccase) inhibitor;
EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor;
EC 1.14.18.1 (tyrosinase) inhibitor;
EC 1.4.3.3 (D-amino-acid oxidase) inhibitor;
NF-kappaB inhibitor;
skin lightening agent
neostigmine
Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.. neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.		2.110quaternary ammonium ionantidote to curare poisoning;
EC 3.1.1.7 (acetylcholinesterase) inhibitor
vincristine
[no description available]		2.110acetate ester;
formamides;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent;
drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
ampicillin
Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.		2.0510beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		2.11101,2,3-triazole
5-phenyl-1,3,4-oxadiazole-2-thiol
5-phenyl-1,3,4-oxadiazole-2-thiol: structure in first source		2.0510
amphotericin b
Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.		2.110antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Hypermelanosis
[description not available]		02.0510
Hyperpigmentation
Excessive pigmentation of the skin, usually as a result of increased epidermal or dermal melanin pigmentation, hypermelanosis. Hyperpigmentation can be localized or generalized. The condition may arise from exposure to light, chemicals or other substances, or from a primary metabolic imbalance.		02.0510
Anemia, Fanconi
[description not available]		02.1310
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		02.1310